E
69.20
0.21 (0.30%)
| Previous Close | 68.99 |
| Open | 68.79 |
| Volume | 5,138,617 |
| Avg. Volume (3M) | 4,931,759 |
| Market Cap | 40,814,157,824 |
| Price / Earnings (TTM) | 26.72 |
| Price / Earnings (Forward) | 29.94 |
| Price / Sales | 6.92 |
| Price / Book | 4.48 |
| 52 Weeks Range | |
| Earnings Date | 4 Feb 2025 - 10 Feb 2025 |
| Profit Margin | 65.86% |
| Operating Margin (TTM) | 29.11% |
| Diluted EPS (TTM) | 2.59 |
| Quarterly Revenue Growth (YOY) | 8.90% |
| Quarterly Earnings Growth (YOY) | 697.80% |
| Total Debt/Equity (MRQ) | 7.35% |
| Current Ratio (MRQ) | 3.46 |
| Operating Cash Flow (TTM) | 806.40 M |
| Levered Free Cash Flow (TTM) | 1.79 B |
| Return on Assets (TTM) | 10.65% |
| Return on Equity (TTM) | 19.14% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Edwards Lifesciences Corporatio | Bearish | Bearish |
AIStockmoo Score
0.5
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 1.0 |
| Average | 0.50 |
|
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Mid Core |
| % Held by Insiders | 0.91% |
| % Held by Institutions | 87.58% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 90.00 (Stifel, 30.06%) | Buy |
| 90.00 (B of A Securities, 30.06%) | Buy | |
| 90.00 (Goldman Sachs, 30.06%) | Buy | |
| Median | 85.00 (22.83%) | |
| Low | 60.00 (Wolfe Research, -13.30%) | Sell |
| Average | 81.33 (17.53%) | |
| Total | 6 Buy, 2 Hold, 1 Sell | |
| Avg. Price @ Call | 72.34 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Stifel | 30 Jan 2025 | 90.00 (30.06%) | Buy | 73.22 |
| 05 Dec 2024 | 75.00 (8.38%) | Hold | 72.43 | |
| Wolfe Research | 16 Jan 2025 | 60.00 (-13.29%) | Sell | 69.86 |
| B of A Securities | 16 Dec 2024 | 90.00 (30.06%) | Buy | 73.91 |
| Citigroup | 11 Dec 2024 | 83.00 (19.94%) | Buy | 73.81 |
| Canaccord Genuity | 05 Dec 2024 | 68.00 (-1.73%) | Hold | 72.43 |
| Goldman Sachs | 05 Dec 2024 | 90.00 (30.06%) | Buy | 72.43 |
| RBC Capital | 05 Dec 2024 | 85.00 (22.83%) | Buy | 72.43 |
| 27 Nov 2024 | 80.00 (15.61%) | Buy | 72.07 | |
| Truist Securities | 05 Dec 2024 | 78.00 (12.72%) | Hold | 72.43 |
| Barclays | 02 Dec 2024 | 88.00 (27.17%) | Buy | 70.53 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |